about
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathwayCD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia veraRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedRationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisAcute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative NeoplasmsRisk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysisAconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.An unusual case of toe ulcerationMethotrexate Is a JAK/STAT Pathway InhibitorJAK2 V617F in myeloid disorders: what do we know now, and where are we headed?Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Experience with ruxolitinib in the treatment of polycythaemia vera.Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsFactor XIII activity mediates red blood cell retention in venous thrombi.Identification of an acquired JAK2 mutation in polycythemia vera.JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Cerebral infarction due to smoker's polycythemia.JAK2(V617F): Prevalence in a large Chinese hospital populationThe orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis.JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.Apoptotic mechanisms in the control of erythropoiesis.Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).Analysis of hemochromatosis gene mutations in 52 consecutive patients with polycythemia vera.Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera.Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor CriterionDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableCombination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cellsJakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.Spleens of myelofibrosis patients contain malignant hematopoietic stem cellsA critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesMechanisms of adverse effects of anti-VEGF therapy for cancer.JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.
P2860
Q24685447-B96277A9-63A6-4FA1-8CA1-88C5C4A1C58BQ24799745-68595ED3-EB02-4110-9EAF-734C2242C066Q26738514-0C7DC704-F8D1-4EA9-B0BC-8BBE98F25AB1Q26772881-F5147B06-7369-4516-AFED-D4D0C488E8FAQ26799790-85399CB9-D0BC-4FD2-86D4-85BD097614E2Q27026453-D4DFDF04-084E-46D1-B0DF-55A163FCFAD2Q27323049-D471DE2E-38D7-48A7-9440-A278DF3B52BCQ28217370-79066A4B-FA54-411F-A6F1-5A614232099DQ28546079-474B8892-45F1-4D0C-A39F-4641B066A336Q33341856-899DE2E0-90FA-47EA-8829-6E62EF3FD865Q33420037-EAFF1E5D-1DFE-4260-8791-2E3219858FC0Q33605624-ACA60FA5-FAB1-45C2-857E-413C74436C06Q33894805-3A52EB6B-9B73-4ECF-A370-024139FE3379Q33944224-B4D69878-289B-410B-A335-F928B1CA76DCQ33947635-3C21591A-4B51-48A1-AFDF-61E000585EA4Q34471806-BD2D0DE9-48BC-4136-928A-0227E9E59EF3Q34487244-710DD18C-7EF5-4D50-8595-812F1455AC8DQ34541582-13B570D8-6009-4AE1-AEF5-689D2116EA34Q35295368-021CA8BF-0ECA-44F5-8F25-48A8D040E9EBQ35433005-728E8A80-5E17-430C-91AE-A7C858019F77Q35433259-050A6320-2F7A-4592-B9A1-D99B365093A5Q35519844-129B1B57-E772-4405-A177-317D52CAB03DQ35615806-32D06B0E-6C27-4A61-BB10-3E4337A966D9Q35743852-81653EFB-F17C-49FF-92F5-0A4B9C7D8E0AQ35745175-9DC06B6E-4D0A-4FC2-B86F-FE66F4C0E262Q35790260-A9364433-B577-4749-9777-53FDE226B849Q35811887-3BD5676F-CA0A-41B1-B7E0-9B5A4A0C0634Q35987416-279EF576-9688-42D7-B622-8CF3984BF7C1Q36069486-888853AC-CEF3-4BB1-8C3D-B69CEB244D02Q36164494-D38F2BA6-8961-4DDA-979C-F050575C49BAQ36182119-4DD27762-6D81-4D4B-8AA7-B8EA127C96AAQ36266377-971F9ACF-1FCD-4145-BCCE-ED3F72A0F078Q36318162-32EF661D-DDC9-4065-8336-98974701A178Q36333764-E717C0A0-F929-4CF2-873B-32760227500FQ36356466-52711321-E117-402B-BFB0-0260FF093926Q36362041-DFA119C0-BB0C-4378-AD32-7EC3479B8D63Q36508949-40D11E4D-A503-4FBE-92BC-B0376303EA8EQ36609627-8CD75E55-FEEB-48F4-9CB0-D6A0CDACB196Q36612537-D3D59AF7-42BF-4ED8-935A-DE7C00F89FFBQ36736105-871AB7EA-5050-4A4B-AFD5-5B2507093488
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Polycythemia vera: myths, mechanisms, and management.
@ast
Polycythemia vera: myths, mechanisms, and management.
@en
Polycythemia vera: myths, mechanisms, and management.
@nl
type
label
Polycythemia vera: myths, mechanisms, and management.
@ast
Polycythemia vera: myths, mechanisms, and management.
@en
Polycythemia vera: myths, mechanisms, and management.
@nl
prefLabel
Polycythemia vera: myths, mechanisms, and management.
@ast
Polycythemia vera: myths, mechanisms, and management.
@en
Polycythemia vera: myths, mechanisms, and management.
@nl
P1433
P1476
Polycythemia vera: myths, mechanisms, and management.
@en
P2093
Jerry L Spivak
P304
P356
10.1182/BLOOD-2001-12-0349
P407
P577
2002-08-08T00:00:00Z